Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia

J Allergy Clin Immunol. 2008 Apr;121(4):1054-6. doi: 10.1016/j.jaci.2007.11.027. Epub 2008 Jan 30.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Base Sequence
  • Benzamides
  • Chronic Disease
  • Drug Resistance, Neoplasm* / genetics
  • Humans
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / immunology*
  • Hypereosinophilic Syndrome / metabolism
  • Imatinib Mesylate
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Piperazines / administration & dosage*
  • Pyrimidines / administration & dosage*
  • Receptor, Platelet-Derived Growth Factor alpha / biosynthesis*
  • Receptor, Platelet-Derived Growth Factor alpha / genetics
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / physiology*
  • mRNA Cleavage and Polyadenylation Factors / biosynthesis*
  • mRNA Cleavage and Polyadenylation Factors / genetics

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Benzamides
  • FIP1L1 protein, human
  • Piperazines
  • Pyrimidines
  • Recombinant Fusion Proteins
  • mRNA Cleavage and Polyadenylation Factors
  • Imatinib Mesylate
  • mepolizumab
  • Receptor, Platelet-Derived Growth Factor alpha